FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial. PMID 41920558 · JAMA Psychiatry · 2026-Jun-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Results of the Pediatric Guideline Adherence and Outcomes (PEGASUS) Program Versus Usual Care Pragmatic Randomized Controlled Trial in Severe Traumatic Brain Injury. PMID 41891786 · Crit Care Med · 2026-Jun-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clozapine After 1 Failed Antipsychotic Drug Trial in First-Episode Psychosis: A Randomized Clinical Trial. PMID 41811299 · JAMA Psychiatry · 2026-Jun-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study. PMID 41777218 · Inflamm Bowel Dis · 2026-Jun-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Nonavalent HPV vaccine to prevent recurrent anal or vulvar high-grade squamous intraepithelial lesions (VIVA trial): A randomized, double-blind, placebo-controlled trial. PMID 41685810 · Int J Cancer · 2026-Jun-01 Trial is oncology-focused, randomized, with a drug intervention and primary results. However, it is not explicitly a Phase III/IIIb trial (phase not stated in abstract; mesh terms do not include 'Phase 3'), and crucially, the primary endpoints are incidence-based outcomes (HSIL recurrence and HPV persistence) reported as proportions and rates, not time-to-event endpoints with Kaplan-Meier curves or hazard ratios. Therefore, it fails the required time-to-event efficacy endpoint criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program. PMID 41655066 · Inflamm Bowel Dis · 2026-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effects of a structured exercise program on motivational outcomes in patients with colon cancer. PMID 41609410 · J Natl Cancer Inst · 2026-Jun-01 The trial is a Phase 3 randomized oncology study with human patients, but it is excluded because it does not have a drug-containing intervention (exercise program vs. health education materials) and does not report a time-to-event efficacy endpoint; it reports on motivational/behavioral outcomes. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| EHealth intervention for quality of life in long-term breast cancer survivors: randomized controlled trial. PMID 41581214 · J Natl Cancer Inst · 2026-Jun-01 The study is an oncology randomized trial reporting on quality of life, not a time-to-event efficacy endpoint. It lacks a drug intervention and is not a Phase III/IIIb or Phase II/III trial. Therefore, it does not meet the eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Accelerated approvals in oncology: Trial design strategies and insights driving successful regulatory outcomes across three decades. PMID 41460153 · Int J Cancer · 2026-Jun-01 The record is a retrospective analysis of regulatory data on multiple oncology drug approvals. It does not meet the inclusion criteria for a single, original, formal-result report of a human malignant-neoplasm Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint. The study design is a review of multiple trials, not a trial report itself. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study. PMID 41296499 · Diabetes Care · 2026-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Treatment Effect of Beta-Blocker Therapy After Acute Myocardial Infarction With Preserved or Mildly Reduced Ejection Fraction: A Systematic Review and Trial Sequential Analysis. PMID 42473525 · Cureus · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| PICCOS: study protocol for pressurised intraperitoneal aerosolised chemotherapy (PIPAC) in the management of cancers of the colon, ovary and stomach: a randomised controlled, phase II trial of efficacy in peritoneal metastases. PMID 42416477 · Pleura Peritoneum · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Plain balloon angioplasty +/- bare metal stenting versus drug-coated balloon angioplasty +/- bare metal stenting versus primary drug-eluting stenting in patients with chronic limb-threatening ischaemia: BASIL-3, an open-label, three-arm, randomised, multi-centre, phase 3 trial. PMID 42381494 · Health Technol Assess · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| 18F-Fluciclovine or 68Ga-PSMA-11 PET/CT-guided Salvage Radiotherapy Changes in Postprostatectomy Biochemical Recurrence: Secondary Analysis of the EMPIRE-2 Trial. PMID 42377125 · Radiology · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial. PMID 42370465 · Health Technol Assess · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study. PMID 42341255 · JCO Precis Oncol · 2026-Jun While the record describes an analysis of a randomized comparison in oncology, it is a secondary, biomarker-driven analysis from a real-world study (FLEX), not a primary result from a definitive Phase III/IIIb or Phase II/III randomized trial. The parent trial's phase is not confirmed in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cardiovascular outcomes and safety associated with statin therapy for primary prevention in older adults with type 2 diabetes: A target trial emulation study. PMID 42340940 · PLoS Med · 2026-Jun The study is an observational cohort study emulating a trial of statins for primary cardiovascular disease prevention in older adults with type 2 diabetes. It is not an oncology study, not a randomized trial, and does not involve a drug intervention for cancer. While it reports time-to-event outcomes (CVD, all-cause mortality), these are not the required cancer-specific endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study. PMID 42339511 · Cancer Med · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK. PMID 42339309 · EClinicalMedicine · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis. PMID 42338692 · Liver Cancer · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer. PMID 42335416 · Am Soc Clin Oncol Educ Book · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Corrigendum to "Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in Indian adults with obesity: A phase III randomized non-inferiority trial" [Metabol Open 30 (2026) 100460]. PMID 42327013 · Metabol Open · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of Quadriceps Strengthening Exercise with Blood Flow Restriction on Knee Angular Velocity, Strength, and Balance in Fencers. PMID 42318262 · J Sports Sci Med · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of Acceptance and Commitment Therapy on Death Anxiety in Cancer Survivors: A Randomized Controlled Trial. PMID 42317021 · Psychooncology · 2026-Jun The study is a randomized controlled trial in cancer survivors, but it evaluates a psychotherapy (ACT), not a drug-containing intervention. The primary endpoint is death anxiety, a quality-of-life measure, not a time-to-event efficacy endpoint (e.g., OS, PFS). It is not a Phase III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Randomized Controlled Phase 3 Trial of Oral Prednisolone Administration Versus Local Triamcinolone Injection Therapy for Esophageal Stricture Prevention After Extensive Endoscopic Submucosal Dissection (JCOG1217). PMID 42313516 · Dig Endosc · 2026-Jun The trial is a randomized Phase III study in a human oncology context with a time-to-event endpoint. However, the drug intervention (prednisolone vs. triamcinolone) is for the prevention of a post-procedural complication (esophageal stricture), not for treating the underlying malignant neoplasm. The efficacy endpoint (stricture-free survival) is not a direct oncological efficacy endpoint (like OS, PFS, DFS). Therefore, it does not meet the core criterion of being a trial of a drug-containing intervention for efficacy against the cancer. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Analysis of Viral Blips Through Week 192 of the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Studies of Doravirine-Based Regimens in Adults Living With Previously Untreated HIV-1. PMID 42281892 · Open Forum Infect Dis · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial. PMID 42273802 · Alzheimers Dement · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-Term Colorectal Cancer Incidence After Adenoma and Serrated Polyp Removal: Results From the Colonprev Trial. PMID 42272346 · United European Gastroenterol J · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Oral Anticoagulation in Systemic Sclerosis-Related Pulmonary Arterial Hypertension-Results From the SPHInX Study. PMID 42266819 · Pulm Circ · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study. PMID 42257510 · Eur J Neurol · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China. PMID 42256683 · EClinicalMedicine · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France). PMID 42256682 · EClinicalMedicine · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Zoliflodacin for uncomplicated gonorrhea: clinical evidence and implications beyond ceftriaxone plus azithromycin. PMID 42254149 · Ann Med Surg (Lond) · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT-035 Study. PMID 42253638 · EJHaem · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus. PMID 42253408 · Metabol Open · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Baclofen Modulates Neural Intrinsic Functional Connectivity in Treatment-Seeking Individuals With Alcohol Use Disorder. PMID 42246466 · Alcohol Clin Exp Res (Hoboken) · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Efficacy of Nicotinamide in Maintaining Mean Deviation in Glaucoma: A Systematic Review. PMID 42244899 · Cureus · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Dietary inflammatory index and unfavorable dietary patterns associated with ischemic stroke in China. PMID 42242853 · Asia Pac J Clin Nutr · 2026-Jun The study is an oncology randomized Phase III trial with primary results, but it does not meet the inclusion criteria because the intervention is a non-drug nutritional product (FSMP) and the primary endpoint is not a time-to-event efficacy measure (it is a change in a biochemical marker). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [177Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial. PMID 42225102 · Lancet Oncol · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Clinical implications of skincare: lessons from placebo-controlled dermatology trials. PMID 42222690 · Skin Health Dis · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Personalised and Gamified Digital Decision Aid for Colorectal Cancer Screening: A Randomised Controlled Pilot Study. PMID 42216438 · Cancer Med · 2026-Jun This is a randomized pilot study of a digital decision aid for colorectal cancer screening, not a drug intervention trial, and does not have a time-to-event efficacy endpoint. It fails the core eligibility criteria of having a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis. PMID 42206806 · J Comp Eff Res · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy of an internal traction device in colorectal endoscopic submucosal dissection: a multicenter randomized controlled trial. PMID 42191957 · Surg Endosc · 2026-Jun 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Safety-Driven Response Adaptive Randomization: An Application in Noninferiority Oncology Trials. PMID 42186850 · Stat Med · 2026-Jun The record is a methodological study proposing and simulating a new trial design (SAFER), not an original formal-result report of a specific Phase III trial. While it references a Phase III trial (CAPP-IT) and is oncology-related, it does not present primary efficacy results (time-to-event or otherwise) for that or any trial. |
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The use of memantine for prevention of Alzheimer's disease: Pilot feasibility study rationale and protocol. PMID 42179865 · Contemp Clin Trials Commun · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of Fospropofol on intraoperative hemodynamics in patients undergoing Supratentorial tumor resection: A randomized controlled trial. PMID 42176429 · J Clin Anesth · 2026-Jun The study is a randomized, human, oncology trial with a drug intervention (fospropofol vs. propofol) and original results. However, it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary outcome is a hemodynamic measure (area under the threshold for mean arterial pressure <65 mmHg), and secondary outcomes are other perioperative clinical measurements, not oncology efficacy endpoints. Phase is not specified as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Therapeutic update on alopecia areata: a critical review of standard and emerging targeted therapies. PMID 42176145 · Inflammopharmacology · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Palbociclib in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer and Bone-Only Metastasis: A Systematic Literature Review. PMID 42173733 · Clin Breast Cancer · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Postmastectomy Radiotherapy With Immediate Implant Reconstruction: Treatment Fractionation, Implant Plane, and Clinical Outcomes. PMID 42173060 · Clin Breast Cancer · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Estimated efficacy of the adjuvanted RSVPreF3 vaccine against diverse and worldwide predominant RSV strains, irrespective of RSV F protein variation: results of a post-hoc analysis from the AReSVi-006 trial. PMID 42172919 · EBioMedicine · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |